Who to call at Corcept Therapeutics Incorporated, and when
Fundz watches for the moments Corcept Therapeutics Incorporated starts buying, and tells you who to reach.
- An alert the day Corcept Therapeutics Incorporated raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Corcept Therapeutics Incorporated, from your own LinkedIn network
Corcept Therapeutics Incorporated
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.corcept.comThe seat is still open. No replacement has been named 31 days after this filing.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Sean Maduck, President of Corcept Endocrinology, resigned effective October 1, 2026, with no disagreements cited. The company transitioned him to a consulting services agreement, representing a leadership change that may impact strategic direction.
Key Takeaways
Sean Maduck's resignation is effective October 1, 2026, with no operational or financial disagreements disclosed
The company retained Maduck through a Consulting Services Agreement commencing on his resignation date
2 more takeaways
Related Filings (1)
1 more filing from Corcept Therapeutics Incorporated in the last 90 days
Filing Overview
What This Means
Corcept Therapeutics Incorporated filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.